B and T Cell Epitope‐Based Peptides Predicted from Evolutionarily Conserved and Whole Protein Sequences of Ebola Virus as Vaccine Targets. (May 2016)

• Record Type: Journal Article
• Authors: Yasmin, T.; Nabi, A. H. M. Nurun
• Is Part Of: Scandinavian journal of immunology. Volume 83:Number 5(2016:May)
• Page Start: 321
• Page End: 337
• Publication Date: 2016-05
• Subjects: Immunology -- Periodicals; 571.96
• DOI: 10.1111/sji.12425
• Languages: English
• ISSNs: 0300-9475

Abstract

Abstract: Ebola virus (EBV) has become a serious threat to public health. Different approaches were applied to predict continuous and discontinuous B cell epitopes as well as T cell epitopes from the sequence‐based and available three‐dimensional structural analyses of each protein of EBV. Peptides ' 79 VPSATKRWGFRSGVPP 94 ' from GP1 and ' 515 LHYWTTQDEGAAIGLA 530 ' from GP2 of Ebola were found to be the consensus peptidic sequences predicted as linear B cell epitope of which the latter contains a region 519 TTQDEG 524 that fulfilled all the criteria of accessibility, hydrophilicity, flexibility and beta turn region for becoming an ideal B cell epitope. Different nonamers as T cell epitopes were obtained that interacted with different numbers of MHC class I and class II alleles with a binding affinity of <100 nm . Interestingly, these alleles also bound to the MHC class I alleles mostly prevalent in African and South Asian regions. Of these, 'LANETTQAL' and 'FLYDRLAST' nonamers were predicted to be the most potent T cell epitopes and they, respectively, interacted with eight and twelve class I alleles that covered 63.79% and 54.16% of world population, respectively. These nonamers were found to be the core sequences of 15mer peptides that interacted with the most common class II allele, HLA‐DRB1*01:01. They were further validated for their binding to specific class I alleles using docking technique. Thus, these predicted epitopes may be used as vaccine targets against EBV and can be validated in model hosts to verify their efficacy as vaccine.